US Edition
4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME
Summary by Eyewire+
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
4DMT Provides New 60-Week Results for Gene Therapy Candidate for DME
4D Molecular Therapeutics (4DMT) announced interim results from its SPECTRA phase 2a clinical trial evaluating 4D-150 for diabetic macular edema (DME). The data were presented at the 43rd Annual American Society of Retina Specialists (ASRS) scientific meeting by David Almeida, MD, PhD.[1] Key Takeaways 1. Durable Visual and Anatomic Response at Phase 3 Dose Patients receiving the Phase 3 dose (3E10 vg/eye) of 4D-150 demonstrated: +9.7 letter…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
